Nuvectis Pharma To Participate in Upcoming Investor Conferences
Nuvectis Pharma (NVCT) will participate in two upcoming investor conferences in September 2026 to discuss its clinical-stage pipeline in complement-related diseases and oncology.
Rhea-AI Summary
Nuvectis Pharma (NVCT) will participate in two upcoming investor conferences in September 2026 to discuss its clinical-stage pipeline in complement-related diseases and oncology.
The company joins the 2026 Cantor Global Healthcare Conference for a fireside chat on Friday, September 11, 2026 at 9:10 AM ET, and the H.C. Wainwright 28th Annual Global Investment Conference for a company presentation on Monday, September 14, 2026 at 12:00 PM ET. Webcasts for both events will be accessible through links provided by the organizers and via the Investors section of Nuvectis’ website.
Nuvectis is developing ciprocopan (NXP100), a complement Factor B inhibitor and its lead candidate, recently approved in China for treating PNH patients previously untreated with complement inhibitors, as a once-daily oral option for complement-mediated diseases. Its oncology pipeline also includes NXP200, an oral brain-penetrant BRAF inhibitor targeting BRAF V600X and non-V600 mutations, and NXP900, an oral inhibitor of SRC family kinases SRC and YES1 intended to comprehensively block SRC signaling.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences:
- 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast link: Cantor Fireside Chat.
- H.C. Wainwright 28th Annual Global Investment Conference: Company Presentation, Monday, September 14, 2026 at 12:00 PM ET. Webcast link: Nuvectis Presentation.
A webcast of the presentations will be available in the Investors section of Nuvectis’ website at www.nuvectis.com.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.
The company’s lead drug candidate is ciprocopan, a Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors. In PNH and other complement-mediated diseases, ciprocopan is expected to provide a meaningful convenience advantage as a once-daily, oral treatment option for diseases requiring lifelong treatment.
NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer, with best-in-class potential.
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, including SRC and YES1 intended to inhibit the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the SRC signaling pathway.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When will Nuvectis Pharma (NVCT) present at the 2026 Cantor Global Healthcare Conference?
Nuvectis Pharma is scheduled for a fireside chat at the 2026 Cantor Global Healthcare Conference on Friday, September 11, 2026 at 9:10 AM ET. Investors can access the webcast via the conference link and through the Investors section of the company’s website.
What is the date and time of Nuvectis Pharma’s presentation at the H.C. Wainwright 28th Annual Global Investment Conference for NVCT?
Nuvectis Pharma will deliver a company presentation at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 at 12:00 PM ET. A webcast of the presentation will be available through a dedicated link and on the company’s investor webpage.
How can investors access the Nuvectis Pharma (NVCT) webcasts for the September 2026 conferences?
Webcasts of Nuvectis Pharma’s fireside chat at the Cantor conference and its presentation at the H.C. Wainwright conference will be available via the respective webcast links provided and in the Investors section of the company’s website at www.nuvectis.com.
What is Nuvectis Pharma’s lead drug candidate ciprocopan (NXP100) mentioned in the NVCT conference announcement?
Ciprocopan (NXP100) is Nuvectis Pharma’s lead complement Factor B inhibitor for complement-mediated diseases. It has been recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors and is designed as a once-daily oral therapy.
Which oncology drug candidates will Nuvectis Pharma (NVCT) likely highlight at the 2026 investor conferences?
Nuvectis Pharma’s oncology pipeline includes NXP200, an oral, brain-penetrant, paradox-breaker BRAF inhibitor for BRAF V600X and Class II/III non-V600-mutated solid tumors, and NXP900, an oral inhibitor of SRC family kinases SRC and YES1 intended to shut down SRC signaling in advanced cancers.